DLBCL and FL patients experience considerable economic burden during the first year after diagnosis.
DLBCL & Follicular Lymphoma Year in Review
New data support PFS as a surrogate endpoint for OS in future trials evaluating chemoimmunotherapy in DLBCL.
In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment with R-CHOP alone.
The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.
Follicular large cleaved cell lymphoma is frequently misclassified, according to researchers.
In this interview, Dr. Frederick Locke discusses the promise of CAR T-cell therapy for lymphomas, and how this gene therapy could offer hope for patients who don't respond to standard treatments.
Lenalidomide plus rituximab failed to demonstrate superiority over standard of care for follicular lymphoma in the phase III RELEVANCE trial.